Renalytix LinkedIn Contact Us
Renalytix Investors

Recent Releases

  • Holding(s) in Company
    30 October 2025 16:58 GMT
    read more
  • Holding(s) in Company
    28 October 2025 16:04 GMT
    read more
  • Confirmation of receipt of £860k R&D tax credits
    27 October 2025 07:00 GMT
    read more
  • Holding(s) in Company
    24 October 2025 10:12 GMT
    read more
  • Holding(s) in Company
    23 October 2025 09:09 GMT
    read more
view all

Recent Events

  • Renalytix Third Quarter Fiscal Year 2024 Earnings Call and Webcast
    15 May 2024 08:30 ET
    read more
  • BTIG Conference
    13 February 2024 - 14 February 2024 ET
    read more
  • Renalytix First Quarter Fiscal Year 2024 Earnings Call and Webcast
    17 November 2023 08:30 ET
    read more
  • Renalytix Fourth Quarter Fiscal Year 2023 Earnings Call and Webcast
    28 September 2023 08:30 ET
    read more
view all

Who we are

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.  Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.

read more

Company metrics

Leading the market year after year

  • Addressing one of the largest and costliest unmet needs in healthcare
  • Listed on AIM (November, 2018) and OTCQB (October, 2024)
  • FDA Approves KidneyIntelX.dkd™ (June 2023)

Stock performance